tiprankstipranks
Trending News
More News >
FunPep Company Limited (JP:4881)
:4881
Japanese Market

FunPep Company Limited (4881) AI Stock Analysis

Compare
0 Followers

Top Page

JP

FunPep Company Limited

(4881)

Rating:38Underperform
Price Target:
FunPep Company Limited receives a low overall stock score due to substantial financial challenges, including negative profitability and cash flow. Technical indicators reflect bearish momentum, while valuation metrics are unfavorable due to persistent losses. The lack of debt offers some stability, but the company faces significant hurdles in improving its financial health.

FunPep Company Limited (4881) vs. iShares MSCI Japan ETF (EWJ)

FunPep Company Limited Business Overview & Revenue Model

Company DescriptionFunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.
How the Company Makes MoneyFunPep Company Limited generates revenue primarily through the development and commercialization of its peptide-based drugs. The company earns income by licensing its proprietary technologies and products to pharmaceutical companies and healthcare organizations. Additionally, FunPep may benefit from research and development collaborations, where it partners with other entities to co-develop treatments and shares in the resultant profits. The company's earnings are also bolstered by potential government grants or funding for research initiatives, as well as milestone payments and royalties from successfully commercialized drugs.

FunPep Company Limited Financial Statement Overview

Summary
FunPep Company Limited faces significant financial challenges, primarily due to negative profitability and cash flow metrics. The company's strong equity position and lack of debt provide some financial stability, but the inability to generate positive revenue and cash flows presents a major concern. The company needs to address operational inefficiencies and improve revenue generation to enhance financial health.
Income Statement
30
Negative
FunPep Company Limited has shown inconsistent revenue generation over the years, with a significant decline in revenue in recent periods. The company reported a sharp drop in revenue from 2019 to 2024, and the net income remains negative, indicating sustained losses. Both the EBIT and EBITDA margins are negative, highlighting ongoing operational challenges and inefficiencies.
Balance Sheet
45
Neutral
The company maintains a strong equity base with no debt, resulting in a very low debt-to-equity ratio. However, the return on equity is negative due to persistent net losses, which impacts overall equity performance. The equity ratio remains healthy, indicating a strong asset base relative to liabilities.
Cash Flow
35
Negative
Operating cash flows are consistently negative, pointing to challenges in generating cash from core operations. Free cash flow remains negative, compounded by the absence of capital expenditure. The high operating cash flow to net income ratio indicates cash flow issues that align with reported net losses. However, the company has strong cash reserves, which provides some liquidity cushion.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.13M530.00K1.07M126.87M2.97M
Gross Profit-535.58M-680.29M-911.29M-535.63M-362.01M
EBITDA-859.23M-952.00M-1.16B-745.04M-563.52M
Net Income-889.09M-933.42M-1.17B-682.26M-507.93M
Balance Sheet
Total Assets3.11B2.49B2.99B3.36B3.72B
Cash, Cash Equivalents and Short-Term Investments2.35B1.79B2.25B3.01B3.62B
Total Debt0.000.000.000.000.00
Total Liabilities563.18M189.32M298.11M188.67M152.09M
Stockholders Equity2.55B2.30B2.69B3.18B3.57B
Cash Flow
Free Cash Flow-537.60M-989.87M-1.07B-892.79M-413.95M
Operating Cash Flow-536.74M-988.82M-1.05B-887.47M-413.95M
Investing Cash Flow-30.83M-1.05M-19.14M-4.75M0.00
Financing Cash Flow1.12B537.81M245.13M282.68M3.14B

FunPep Company Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price109.00
Price Trends
50DMA
108.46
Positive
100DMA
114.67
Negative
200DMA
125.81
Negative
Market Momentum
MACD
-1.30
Positive
RSI
47.37
Neutral
STOCH
25.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4881, the sentiment is Neutral. The current price of 109 is below the 20-day moving average (MA) of 112.60, above the 50-day MA of 108.46, and below the 200-day MA of 125.81, indicating a neutral trend. The MACD of -1.30 indicates Positive momentum. The RSI at 47.37 is Neutral, neither overbought nor oversold. The STOCH value of 25.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4881.

FunPep Company Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (57)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥4.65B18.36
18.71%33.40%
59
Neutral
¥8.35B
1473.61%22.80%
57
Neutral
7.56B6.13-28.19%5.55%26.41%6.62%
54
Neutral
¥5.85B
12.66%24.73%
43
Neutral
¥4.21B
3.10%-25.31%-61.72%
38
Underperform
¥4.30B
1056.04%21.63%
37
Underperform
¥5.09B
-96.64%8.92%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4881
FunPep Company Limited
110.00
-53.00
-32.52%
JP:2385
Soiken Holdings Inc.
161.00
-1.17
-0.72%
JP:4570
Immuno-Biological Laboratories Co., Ltd.
491.00
-24.00
-4.66%
JP:4591
Ribomic, Inc.
119.00
29.00
32.22%
JP:4594
BrightPath Biotherapeutics Co.Ltd.
67.00
0.00
0.00%
JP:4884
Kringle Pharma, Inc.
859.00
-196.00
-18.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025